Entrada Therapeutics announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable to skipping exon 44.

- Posted in Research

Entrada Therapeutics, who received early funding from CureDuchenne to advance their Endosomal Escape Vehicle Platform, today announced positive initial data from their Phase 1/2 ELEVATE-44-201 study in DMD patients amenable to skipping exon 44.

Read press release HERE

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate